The third case (Case 23) had a favourable initial response to treatment with cobimetinib (by compassionate access) after a BRAF rearrangement was identified in a primary pancreatic spindle cell sarcoma; however, this case had progressive disease at 3.8 months and died approximately 5 months after treatment commenced [13]. This evidence concerns the gene BRAF and spindle cell sarcoma.